All news - Pipelinereview
WEB2 days ago — LEHI, UT, USA I September 23, 2024 I Halia Therapeutics, Inc. (Halia), a clinical-stage biopharmaceutical company advancing novel therapies for inflammation-related diseases, today announced promising preclinical results from their investigational compound HT-6184, combined with the GLP-1 agonist semaglutide. The study revealed significant weight loss in a diet-induced obesity (DIO) mouse ...
PipelineReview.com. Biopharmaceutical News & Clinical Trials
WEBPipelineReview.com is powered by La Merie Business Intelligence For immediate assistance, please call us during business hours: Mon-Fri 10:00am - 05:00pm; GMT+01 La Merie Publishing - Ulrich Martin Veinat Puigsec - Can Magí s/n | 17862 Vallfogona de Ripollès | Spain | T +34-87-200 1365 | Email [email protected]
Fusion Pharmaceuticals to Expand Pipeline with Acquisition of IPN …
WEBMar 2, 2021 — Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of our expertise.
Treadwell Therapeutics Announces a Presentation at the 2021 SITC …
WEBNov 14, 2021 — NEW YORK, NY, USA I November 12, 2021 I Treadwell Therapeutics, a clinical-stage biotechnology company developing novel medicines for highly aggressive cancers, today announced a presentation for the Company’s CFI-402411 program, an oral, first-in-class inhibitor of Hematopoietic Progenitor Kinase 1 (HPK1) a negative regulator of immune cell activation, at the 36 th Society for Immunotherapy ...
Gemini Therapeutics Enrolls First Patient in Phase 2a Study of …
WEBSep 10, 2020 — – Enrollment initiated in Phase 1 MAD study in patients with high-risk genetic variants for dry AMD – – Phase 1 topline results demonstrate promising safety profile, with no treatment-related adverse events as well as PK and biomarker changes in genetically defined dry AMD – CAMBRIDGE, MA, USA I September 10 ,2020 I Gemini Therapeutics, a clinical stage precision medicine company ...
Axsome Therapeutics Announces Topline Results of the STRIDE-1 …
WEBMar 31, 2020 — Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of our expertise.
FDA grants Carmell Therapeutics Expedited Review for CT-101, …
WEBApr 27, 2020 — Carmell to begin enrolling in pivotal clinical program for first-of-its-kind Plasma-based Bioactive Material product used in long-bone fractures as an adjunctive treatment. PITTSBURGH, PA, USA I April 27, 2020 ICarmell Therapeutics, a pioneer in the development and commercialization of innovative Plasma-based Bioactive Materials (PBMs) to accelerate bone and soft tissue healing, announced that ...
Novartis announces discontinuation of CIRRUS-1 study of CFZ533 ...
WEBSep 4, 2021 — BASEL, Switzerland I September 03, 2021 I Novartis today announced that following an interim analysis of data from the CIRRUS-1 study, a decision has been taken to discontinue the trial.. The analysis indicated that CFZ533 (iscalimab)-based treatment is less efficacious compared to tacrolimus-based treatment in the prevention of organ rejection in patients receiving a kidney transplant.
Transaction includes actinium-based clinical-stage radioconjugate ...
WEBMar 19, 2024 — Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of our expertise.
Kymera Therapeutics Presents New Preclinical Data for KT-621, a …
WEBMay 23, 2024 — KT-621, a potent, selective, oral STAT6 degrader, demonstrated comparable or superior activity to dupilumab in preclinical studies including an asthma model shared at the ATS Annual Meeting